EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Intravenous versus oral tranexamic acid in shoulder arthroplasty

Tarishi Parmar, Akin Adio, Mohammad Daher, Adam Khan, John Horneff, Joseph Abboud

Archives of Orthopaedic and Trauma Surgery · 19.07.2026 · 146 (1)

DOI: 10.1007/s00402-026-06426-w ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Archives of Orthopaedic and Trauma Surgery, online erschienen am 19.07.2026. Verfasst von Tarishi Parmar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, USA. txp539@students.jefferson.edu. Hauptthemen laut MEDLINE: Arthroplasty, Replacement, Shoulder, Tranexamic Acid, Antifibrinolytic Agents, Blood Loss, Surgical. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Tranexamic acid (TXA) is used in shoulder arthroplasty to reduce blood loss. While intravenous (IV) TXA is standard, oral TXA offers advantages in cost and administration. This study compares 90-day complications and postoperative laboratory values between IV and oral TXA in total shoulder arthroplasty (TSA).

Methods

A retrospective cohort study using TriNetX identified adults undergoing primary TSA (2005–2025) receiving TXA on the day of surgery, stratified by route (IV vs. oral). One-to-one propensity score matching was performed. Ninety-day outcomes included transfusion, thromboembolic events, cardiac and renal complications, neurologic events, infection, wound dehiscence, readmissions, emergency department visits, opioid utilization, and mortality. Postoperative laboratory outcomes included hemoglobin, erythrocyte count, hematocrit, and platelet count. Outcomes were compared using odds ratios (ORs) with 95% confidence intervals (CIs) and t tests where appropriate.

Results

After matching, 5722 patients were included in each cohort. No significant differences were observed between IV and oral TXA in 90-day transfusion rates ( P = 0.873) or thromboembolic events, including deep vein thrombosis and pulmonary embolism. Rates of myocardial infarction, stroke, cardiac ischemia, acute renal failure, infection, readmission, emergency department visits, opioid use, and mortality were also comparable between groups (all P > 0.05). Postoperative laboratory values, including hemoglobin, erythrocyte count, hematocrit, and platelet count, did not differ significantly between IV and oral TXA cohorts (all P > 0.14).

Conclusion

In this large propensity-matched analysis, oral TXA demonstrated equivalent safety, complication rates, and postoperative laboratory profiles compared with IV TXA following TSA. These findings support oral TXA as a clinically effective alternative to IV administration, offering potential advantages in cost reduction and resource utilization without compromising patient safety. Future prospective studies should evaluate optimal dosing strategies, patient-specific selection criteria, and formal cost-effectiveness analyses to further define the role of oral TXA in shoulder arthroplasty pathways. Level of evidence III, Retrospective Cohort Study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthroplasty, Replacement, ShoulderTranexamic AcidAntifibrinolytic AgentsBlood Loss, SurgicalHumansRetrospective StudiesAdministration, OralFemaleMaleAgedPostoperative ComplicationsAdministration, IntravenousMiddle AgedBlood Transfusion

Stichwörter der Autor:innen

Blood lossCost-effectivenessOral vs intravenousShoulder arthroplastyTranexamic acidTransfusion

Substanzen

Tranexamic AcidAntifibrinolytic Agents

Autor:innen und Institutionen

  • Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, USA. txp539@students.jefferson.edu.
  • Division of Shoulder and Elbow Surgery, Rothman Orthopaedics, Philadelphia, USA. txp539@students.jefferson.edu.
  • Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
  • Division of Shoulder and Elbow Surgery, Rothman Orthopaedics, Philadelphia, USA.
  • Southern California Permanente Medical Group, Kaiser Permanente, Panaroma city, USA.
  • Division of Shoulder and Elbow Surgery, Department of Orthopaedics, University of Pennsylvania, Philadelphia, USA.

Zitieren

APA

Parmar, T., Adio, A., Daher, M., Khan, A., Horneff, J., & Abboud, J. (2026). Intravenous versus oral tranexamic acid in shoulder arthroplasty. Archives of Orthopaedic and Trauma Surgery, 146(1). https://doi.org/10.1007/s00402-026-06426-w

Vancouver

Parmar T, Adio A, Daher M, Khan A, Horneff J, Abboud J. Intravenous versus oral tranexamic acid in shoulder arthroplasty. Archives of Orthopaedic and Trauma Surgery. 2026;146(1). doi:10.1007/s00402-026-06426-w

BibTeX
@article{Parmar2026,
  author = {Parmar, Tarishi and Adio, Akin and Daher, Mohammad and Khan, Adam and Horneff, John and Abboud, Joseph},
  title = {Intravenous versus oral tranexamic acid in shoulder arthroplasty},
  journal = {Archives of Orthopaedic and Trauma Surgery},
  year = {2026},
  volume = {146},
  number = {1},
  doi = {10.1007/s00402-026-06426-w}
}
Kostenlos starten →